These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 30945965)
1. Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States. Klink AJ; Chmielowski B; Feinberg B; Ahsan S; Nero D; Liu FX J Manag Care Spec Pharm; 2019 Aug; 25(8):869-877. PubMed ID: 30945965 [TBL] [Abstract][Full Text] [Related]
2. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma. Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578 [No Abstract] [Full Text] [Related]
3. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. van Boemmel-Wegmann S; Brown JD; Diaby V; Huo J; Silver N; Park H JCO Oncol Pract; 2022 Jan; 18(1):e163-e174. PubMed ID: 34228489 [TBL] [Abstract][Full Text] [Related]
4. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124 [No Abstract] [Full Text] [Related]
5. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070 [No Abstract] [Full Text] [Related]
6. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461 [TBL] [Abstract][Full Text] [Related]
7. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data. Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895 [No Abstract] [Full Text] [Related]
8. A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States. Norden AD; Korytowsky B; You M; Kim Le T; Dastani H; Bobiak S; Singh P J Manag Care Spec Pharm; 2019 Apr; 25(4):428-436. PubMed ID: 30917077 [TBL] [Abstract][Full Text] [Related]
9. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis. Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Kim N; Yi E; Michaud K J Manag Care Spec Pharm; 2022 Sep; 28(9):1008-1020. PubMed ID: 36001102 [No Abstract] [Full Text] [Related]
10. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States. Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733 [No Abstract] [Full Text] [Related]
11. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States. Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177 [TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States. Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443 [No Abstract] [Full Text] [Related]
13. Economic Burden of Illness in Adult Patients with Nocturia. Dmochowski R; Brucker BM; Cole E; Kawahara S; Pulicharam R; Burk C; Tung A; Hale D J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816 [TBL] [Abstract][Full Text] [Related]
14. Health care utilization and costs associated with functional status in patients with psoriatic arthritis. Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Hass S; Hur P; Kim N; Yi E; Michaud K J Manag Care Spec Pharm; 2022 Sep; 28(9):997-1007. PubMed ID: 36001101 [No Abstract] [Full Text] [Related]
16. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968 [TBL] [Abstract][Full Text] [Related]
17. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819 [TBL] [Abstract][Full Text] [Related]
18. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population. To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937 [No Abstract] [Full Text] [Related]
19. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer. West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067 [No Abstract] [Full Text] [Related]
20. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer. J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]